MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Epidemiologic And Clinical Features Of Psychiatric Disorders In Patients With Parkinson’s Disease – A Retrospective Cohort Study

    O. Koniashvili, G. Khachiashvili, L. Gabunia (Tbilisi, Georgia)

    Objective: We aimed to assess the average duration of Parkinson's disease at the time patient was diagnosed with specific neuropsychiatric disturbance, to study their prevalence…
  • 2022 International Congress

    Abnormal fractional anisotropy of the tremor network in tremor dominant Parkinson’s disease and Essential tremor plus syndrome

    P. Pal, S. Prasad, R. Bharath, J. Saini (Bangalore, India)

    Objective: To evaluate alterations in fractional anisotropy (FA) of the basal ganglia-thalamocortical (BGTC) and cerebello-thalamocortical (CTC) network in tremor dominant Parkinson’s disease (TDPD) and essential…
  • 2022 International Congress

    Neuroprotective effect of Boswellia dalzielii extracts in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease

    GL. Ndji Otto, H. Adjia, JP. Mingoas Kilekoung (Bertoua, Cameroon)

    Objective: To evaluate the possible protective effects of Boswellia dalzielii in animal model of Parkinson Disease (PD) induced by 6-hydroxydopamine (6-OHDA) injection in the striatum…
  • 2022 International Congress

    Predictive factors for a favorable STN-DBS outcome in Parkinson’s Disease: the role of axial symptoms

    C. Ledda, C. Artusi, G. Imbalzano, M. Bozzali, M. Rizzone, A. Romagnolo, M. Zibetti, L. Lopiano (Turin, Italy)

    Objective: We sought to identify and weight clinical and demographic factors predicting bilateral STN-DBS outcomes. Background: DBS is an established therapeutic option for treating PD…
  • 2022 International Congress

    Relationship between falls and motor state in Parkinson’s disease patients with motor fluctuations

    Y. Okuma (Izunokuni, Japan)

    Objective: To elucidate in which motor state Parkinson’s disease (PD) patients with motor fluctuations fall. Background: Recurrent falls are a disabling feature of PD and…
  • 2022 International Congress

    The barriers and facilitators to satisfaction with botulinum neurotoxin treatment in people with cervical dystonia: a systematic review.

    M. Boyce, A. Mccambridge, L. Bradnam, C. Canning, A. Verhagen (Ultimo, Australia)

    Objective: This systematic review aimed to determine the barriers to satisfaction and facilitators that could improve satisfaction with BoNT therapy for people with CD. Background:…
  • 2022 International Congress

    In vivo synaptic density in parkinsonism

    C. Uribe, KL. Desmond, R. Raymond, K. Smart, A. Reilhac, A. Mena, AE. Lang, G. Kovacs, N. Vasdev, AP. Strafella (Toronto, Canada)

    Objective: To provide first evidence of in vivo binding properties of the [18F]SynVesT-1 tracer (aka [18F]-SDM-8) for the quantification of synaptic density loss in a…
  • 2022 International Congress

    Exploring Young people’s role in providing relief to grandparents affected with Alzheimer

    M. Busgopaul (Port Louis, Mauritius)

    Objective: In some families, children never know that their parents or grandparents are affected by the Parkinson’s Disease (PD). Whatever be the way that Movement…
  • 2022 International Congress

    ADOPTION Study: Status update of a Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson’s Disease

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: This study aims to evaluate the effect of once-daily opicapone (OPC) 50 mg versus an additional dose of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi) to…
  • 2022 International Congress

    Hemichorea secondary to Middle Cerebral Artery (MCA) Stenosis without evidence of ischemic stroke in the basal ganglia

    M. Bruno (Honolulu, USA)

    Objective: To describe two patients who presented with hemichorea from isolated MCA stenosis without evidence of basal ganglia stroke. Background: Hyperkinetic movement disorders can occur…
  • 1
  • 2
  • 3
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley